Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

AVXL

Anavex Life Sciences Corporation

Jan 14 • 04:00PM ET

10.47

Dollar change -0.08
Percentage change -0.76	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB ABBV REGN VRTX GILD AMGN MRK LLY PFE BMY

| Held by: VTI IWM VXF XBI IBB IWN DWAS SCHA VTWO VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.51	Insider Own	3.18%	Shs Outstand	84.80M	Perf Week	-20.14%
Market Cap	888.01M	Forward P/E	4.46	EPS next Y	2.35	Insider Trans	0.00%	Shs Float	82.12M	Perf Month	28.00%
Income	-43.00M	PEG	-	EPS next Q	-0.15	Inst Own	31.93%	Short Float	26.55%	Perf Quarter	94.61%
Sales	0.00M	P/S	-	EPS this Y	-16.03%	Inst Trans	1.21%	Short Ratio	12.04	Perf Half Y	79.59%
Book/sh	1.42	P/B	7.38	EPS next Y	489.50%	ROA	-29.66%	Short Interest	21.80M	Perf Year	74.21%
Cash/sh	1.56	P/C	6.72	EPS next 5Y	-	ROE	-32.81%	52W Range	3.25 - 14.44	Perf YTD	-2.51%
Dividend Est.	-	P/FCF	-	EPS past 5Y	0.85%	ROI	-35.76%	52W High	-27.50%	Beta	0.71
Dividend TTM	-	Quick Ratio	8.86	Sales past 5Y	0.00%	Gross Margin	-	52W Low	222.15%	ATR (14)	1.18
Dividend Ex-Date	-	Current Ratio	8.86	EPS Y/Y TTM	13.82%	Oper. Margin	-	RSI (14)	50.02	Volatility	10.39% 11.95%
Employees	42	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	34.33
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-10.66%	Payout	-	Rel Volume	0.97	Prev Close	10.55
Sales Surprise	-	EPS Surprise	14.27%	Sales Q/Q	-	Earnings	Dec 23 BMO	Avg Volume	1.81M	Price	10.47
SMA20	-3.01%	SMA50	12.16%	SMA200	72.18%	Trades		Volume	1,764,363	Change	-0.76%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-06-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$16 → $11
Jun-23-22	Initiated	Berenberg	Buy	$40
Sep-23-21	Initiated	BTIG Research	Buy	$35
Dec-16-20	Reiterated	H.C. Wainwright	Buy	$14 → $17
Sep-28-20	Initiated	Ladenburg Thalmann	Buy	$12
Feb-27-20	Initiated	Cantor Fitzgerald	Overweight
Jun-18-19	Initiated	Janney	Buy
May-16-18	Resumed	Maxim Group	Buy	$5 → $7
Mar-08-18	Initiated	ROTH Capital	Buy	$6
Feb-13-18	Reiterated	Maxim Group	Buy	$14 → $5
Sep-29-17	Resumed	Noble Financial	Buy	$15
Feb-07-17	Initiated	Noble Financial	Buy	$16
Mar-29-16	Initiated	FBR Capital	Outperform	$10

Show Previous Ratings

Jan-13-25 07:30AM	New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients (GlobeNewswire) -6.06%
Jan-06-25 07:30AM	Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.15%
Dec-31-24 09:40AM	Are Medical Stocks Lagging Anavex Life Sciences (AVXL) This Year? (Zacks)
Dec-30-24 12:00PM	All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Buy (Zacks) -8.84%
Dec-27-24 06:15AM	Anavex price target raised to $42 from $40 at H.C. Wainwright (TipRanks)
01:00AM	Loading…
Dec-26-24 01:00AM	Anavex Life Sciences Faces Manufacturing Challenges Impacting Product Launch and Financial Stability (TipRanks) +15.55%
Dec-24-24 02:00AM	Anavex Life Sciences Corp (AVXL) Q4 2024 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Dec-23-24 11:17PM	Q4 2024 Anavex Life Sciences Corp Earnings Call (Thomson Reuters StreetEvents) +29.55%
07:43AM	Anavex Life Sciences: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease (GlobeNewswire)
Dec-22-24 05:00AM	What To Expect in the Markets This Week (Investopedia)
Dec-16-24 07:30AM	Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024 (GlobeNewswire) +8.51%
Dec-09-24 07:30AM	Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference (GlobeNewswire)
Dec-02-24 07:30AM	Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024 (GlobeNewswire)
07:30AM	Loading…
Nov-26-24 07:30AM	Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's Disease to EMA (GlobeNewswire)
Nov-25-24 07:30AM	Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal (GlobeNewswire)
Oct-31-24 04:00AM	Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024 (GlobeNewswire) +15.94%
Oct-17-24 07:30AM	Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX 3-71 for the Treatment of Schizophrenia (GlobeNewswire)
Oct-09-24 05:01PM	Anavex Life Sciences Corp (AVXL) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Sep-03-24 07:30AM	Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 (GlobeNewswire) -9.30%
Aug-06-24 07:48AM	Anavex Life Sciences: Fiscal Q3 Earnings Snapshot (Associated Press Finance) +5.66%
07:30AM	Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-24 07:30AM	Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 (GlobeNewswire)
Jul-30-24 07:30AM	Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX 2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference (GlobeNewswire) -10.37%
Jul-29-24 08:39AM	Neurodegenerative Disease-Focused Anavex Life Sciences' Alzheimer's Candidate Slows Disease Progression By Almost 39% (Benzinga)
06:22AM	Anavex seek EMA approval despite shaky pivotal Alzheimers trial data (Clinical Trials Arena)
Jul-28-24 05:00PM	Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference (GlobeNewswire)
Jun-20-24 07:30AM	Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
May-22-24 07:30AM	Anavex Life Sciences Announces Expansion of Leadership Team (GlobeNewswire)
12:00PM	Loading…
May-15-24 12:00PM	Anavex Life Sciences (AVXL) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-14-24 10:15AM	NASDAQ: AVXL Investor Notice: Update in Lawsuit for Investors who purchased shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) announced by the Shareholders Foundation (GlobeNewswire) +8.02%
07:30AM	Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-10-24 11:18AM	Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 07:41AM	Anavex Life Sciences: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update (GlobeNewswire)
May-02-24 07:30AM	Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 (GlobeNewswire)
Apr-22-24 05:45AM	Anavex Life Sciences Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your Rights - AVXL (PR Newswire)
Apr-11-24 07:30AM	Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference (GlobeNewswire)
Mar-31-24 01:46AM	AVXL STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights and Remedies Against Anavex Life Sciences Corporation (Business Wire)
Mar-28-24 01:18PM	Investors in Anavex Life Sciences Corporation Should Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your Rights AVXL (GlobeNewswire)
Mar-25-24 11:55AM	AVXL INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences Corporation Investors with Substantial Losses Have Opportunity to Lead Case (GlobeNewswire)
07:30AM	Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-18-24 07:30AM	Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX 3-71 in Schizophrenia (GlobeNewswire) -5.68%
Mar-15-24 05:45AM	Anavex Life Sciences Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your Rights - AVXL (PR Newswire)
Mar-04-24 11:46AM	Anavex Life Sciences Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm (GlobeNewswire)
Feb-26-24 01:14PM	12 $10 Stocks That Will Triple (Insider Monkey)
07:30AM	Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-08-24 09:39AM	Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2024 Earnings Call Transcript (Insider Monkey)
Feb-07-24 07:43AM	Anavex Life Sciences: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update (GlobeNewswire)
Feb-01-24 07:30AM	Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024 (GlobeNewswire)
Jan-31-24 09:55AM	Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 530.68%: Here's is How to Trade (Zacks) -5.09%
Jan-24-24 12:00PM	Anavex Life Sciences (AVXL) Upgraded to Strong Buy: Here's Why (Zacks)
07:30AM	Anavex Life Sciences Reports Publication of ANAVEX 3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX 3-71 in Humans (GlobeNewswire)
Jan-16-24 07:30AM	Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX 3-71 in Schizophrenia (GlobeNewswire)
Jan-12-24 10:10AM	Anavex Life Sciences Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm (GlobeNewswire)
Jan-09-24 08:44AM	Anavex (AVXL): Strong Industry, Solid Earnings Estimate Revisions (Zacks)
Jan-08-24 07:30AM	Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX 2-73) for Treatment of Neurodevelopmental Disorders (GlobeNewswire) +9.15%
Jan-03-24 12:14PM	Anavex Life Sciences Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm (GlobeNewswire) +8.02%
09:51AM	Anavex (AVXL) Falls 35% on Mixed Rett Syndrome Study Results (Zacks)
07:30AM	Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-24 08:00AM	Anavex Life Sciences Provides an Update on Rett Syndrome Program (GlobeNewswire) -35.07%
Dec-20-23 11:09AM	Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA (Zacks) -11.06%
10:45AM	Anavex Life Sciences Stock Sees RS Rating Jump To 86; Is It One To Watch? (Investor's Business Daily)
07:30AM	Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX 2-73 from AVATAR Study in Patients with Rett Syndrome (GlobeNewswire)
Dec-19-23 07:30AM	Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease (GlobeNewswire) +13.20%
Dec-18-23 09:55AM	Does Anavex Life Sciences (AVXL) Have the Potential to Rally 401.47% as Wall Street Analysts Expect? (Zacks)
Dec-01-23 08:09AM	Anavex Life Sciences Corp. (NASDAQ:AVXL) Q4 2023 Earnings Call Transcript (Insider Monkey)
Nov-30-23 09:55AM	Wall Street Analysts See a 468.83% Upside in Anavex Life Sciences (AVXL): Can the Stock Really Move This High? (Zacks)
Nov-27-23 08:10AM	Anavex Life Sciences: Fiscal Q4 Earnings Snapshot (Associated Press Finance) -10.04%
08:00AM	Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update (GlobeNewswire)
Nov-24-23 08:00AM	Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023 (GlobeNewswire) +5.52%
Nov-22-23 08:00AM	Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX 2-73) for Treatment of Insomnia or Anxiety (GlobeNewswire)
Nov-21-23 08:19AM	Anavex (AVXL) Up 12% on Regulatory Update for Alzheimer's Drug (Zacks)
Nov-20-23 08:00AM	Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer's Disease to European Medicines Agency (EMA) (GlobeNewswire) +11.64%
Nov-06-23 08:00AM	Anavex Life Sciences Appoints Senior VP of Regulatory Affairs (GlobeNewswire)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey) +5.77%
Oct-25-23 08:00AM	Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX 3-71 to Prevent Cognitive Decline in Alzheimer's Disease (GlobeNewswire) +8.97%
Sep-14-23 07:30AM	Anavexs Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimers Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration (GlobeNewswire)
Sep-12-23 07:30AM	Anavex Announces Appointment of Dr. Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board (GlobeNewswire)
Aug-08-23 09:43PM	Q3 2023 Anavex Life Sciences Corp Earnings Call (Thomson Reuters StreetEvents) +16.69%
07:58AM	Anavex Life Sciences: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results (GlobeNewswire)
Aug-07-23 07:30AM	Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming ANAVEX®3-71 Clinical Cardiovascular Safety (GlobeNewswire) -6.57%
Aug-02-23 07:30AM	Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Aug-01-23 07:30AM	Anavex Life Sciences to Announce Fiscal 2023 Third Quarter Financial Results on Tuesday August 8, 2023 (GlobeNewswire)
Jul-03-23 07:43AM	We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn (Simply Wall St.)
Jun-28-23 07:30AM	Long-term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX®2-73 (blarcamesine) for Rett Syndrome (GlobeNewswire)
Jun-27-23 07:30AM	Anavex Life Sciences and Partex Group Announce Strategic Partnership to Leverage AI for Drug Development and Healthcare Sales Marketing Building a Patient-Centric Digital Ecosystem (GlobeNewswire)
Jun-20-23 07:30AM	Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference (GlobeNewswire)
Jun-15-23 07:30AM	ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome (GlobeNewswire)
Jun-12-23 07:30AM	Anavex Life Sciences Reports Publication in Medical Journal Signifying Continued Commitment for Improvement of the Rett Syndrome Caregiver Outcome Measure RSBQ (GlobeNewswire) -5.41%
Jun-08-23 09:40AM	Is Anavex Life Sciences (AVXL) Outperforming Other Medical Stocks This Year? (Zacks)
Jun-06-23 07:30AM	Anavex Life Sciences Announces Completion of ANAVEX(®)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial (GlobeNewswire)
Jun-01-23 07:30AM	ANAVEX Announces Issuance of New U.S. Intellectual Property Compositions Patent for ANAVEX®2-73 (blarcamesine) (GlobeNewswire)
May-31-23 09:55AM	Wall Street Analysts Think Anavex Life Sciences (AVXL) Could Surge 338.45%: Read This Before Placing a Bet (Zacks)
May-15-23 09:55AM	Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 342.31%: Here's is How to Trade (Zacks)
May-10-23 02:47PM	Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2023 Earnings Call Transcript (Insider Monkey)
May-09-23 09:51PM	Q2 2023 Anavex Life Sciences Corp Earnings Call (Thomson Reuters StreetEvents) +7.85%

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Donhauser Peter D.O.	Director	Jun 14 '24	Buy	3.64	2,835	10,319	5,000	Jun 17 07:30 AM
Thomas Steffen	Director	May 15 '24	Buy	4.52	5,000	22,600	5,000	May 17 06:01 AM
MISSLING CHRISTOPHER U	President and CEO	Mar 28 '24	Option Exercise	1.32	73,380	96,862	1,323,590	Apr 01 06:00 PM
MISSLING CHRISTOPHER U	President and CEO	Mar 28 '24	Sale	5.11	73,380	374,972	1,250,210	Apr 01 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVXL

Anavex Life Sciences Corporation

Upgrade your FINVIZ experience